报价延迟最少15分钟:2026/04/29 02:35 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9224 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.20/-0.20
|
|
企业价值
375.82M
|
| 资产负债 |
|
每股账面净值
1.09
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
85.33M
|
|
每股收益
0.27
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific. |
